Premium
Resveratrol suppresses the myofibroblastic phenotype and fibrosis formation in kidneys via proliferation‐related signalling pathways
Author(s) -
Zhang Xing,
Lu Hong,
Xie Shuangshuang,
Wu Cunzao,
Guo Yangyang,
Xiao Yanyi,
Zheng Shizhang,
Zhu Hengyue,
Zhang Yan,
Bai Yongheng
Publication year - 2019
Publication title -
british journal of pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.432
H-Index - 211
eISSN - 1476-5381
pISSN - 0007-1188
DOI - 10.1111/bph.14842
Subject(s) - resveratrol , myofibroblast , epithelial–mesenchymal transition , fibrosis , pi3k/akt/mtor pathway , cancer research , wnt signaling pathway , signal transduction , protein kinase b , hedgehog signaling pathway , chemistry , mapk/erk pathway , microbiology and biotechnology , biology , pathology , downregulation and upregulation , medicine , pharmacology , biochemistry , gene
Background and Purpose Renal fibrosis acts as the common pathway leading to the development of end‐stage renal disease. Previous studies have shown that resveratrol has anti‐fibrotic activity, but its potential molecular mechanisms of action are not well understood. Experimental Approach The anti‐fibrotic effects of resveratrol were assayed in a rat model of unilateral ureteral obstruction (UUO) in vivo and in fibroblasts and tubular epithelial cells (TECs) stimulated by TGF‐β1 in vitro. Gene and protein expression levels were analysed by PCR, Western blotting, and immunohistochemical staining. Key Results Resveratrol inhibits the myofibroblastic phenotype and fibrosis formation in UUO kidneys by targeting fibroblast–myofibroblast differentiation (FMD) and epithelial–mesenchymal transition (EMT). The anti‐fibrotic effects of resveratrol correlated with decreased proliferation of TECs in the interstitium and tubules, resulting in suppressed activity of the proliferation‐related signalling pathways, including that of the MAPK, PI3K/Akt, Wnt/β‐catenin, and JAK2/STAT3 pathways. Resveratrol treatment suppressed TGF‐β1‐induced FMD and the expression of the myofibroblastic phenotype in fibroblasts in vitro by antagonizing the activation of proliferation‐related signalling. Similarly, TGF‐β1‐mediated overactivation of the proliferation‐related signalling in TECs induced EMT, and the myofibroblastic phenotype was suppressed by resveratrol. The anti‐fibrotic and anti‐proliferative effects of resveratrol were associated with the inactivation of Smad2/3 signalling and resulted in a partial reversal of FMD and EMT and the inhibition of the myofibroblastic phenotype. Conclusions and Implications Resveratrol suppresses the myofibroblastic phenotype and fibrosis formation in vivo and in vitro via proliferation‐related pathways, making it a potential therapeutic agent for preventing renal fibrosis.